1.88  0 (0%)		04-06 09:46
Open: 1.69 High: 1.8899 Volume: 31,523		Pre. Close: 1.88 Low: 1.69 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	15.87	1-year :	24.52
Resists	First :	13.59	Second :	21
Pivot price	1.85
Supports	First :	1.6	Second :	1.33
MAs	MA(5) :	1.87	MA(20) :	5.21
	MA(100) :	14.83	MA(250) :	0
MACD	MACD :	-3.1	Signal :	-3.3
%K %D	K(14,3) :	60.4	D(3) :	31
RSI	RSI(14): 25.7
52-week	High :	40.31	Low :	1.6

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ APUS ] has closed below upper band by 39.1%. Bollinger Bands are 98.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.88 - 1.89	1.89 - 1.9
Low:	1.85 - 1.87	1.87 - 1.88
Close:	1.86 - 1.88	1.88 - 1.9

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.

Wed, 22 Apr 2026
Apimeds Faces NYSE Non-Compliance Over Delayed 10-K Filing - TipRanks

Wed, 22 Apr 2026
Apimeds Pharmaceuticals US Received Notice of Noncompliance - TradingView

Wed, 22 Apr 2026
Late 10-K puts Apimeds (NYSE: APUS) at risk of NYSE delisting - Stock Titan

Wed, 22 Apr 2026
APUS (Apimeds Pharmaceuticals US Inc.) posts Q1 2025 loss per share of $0.12 amid rising operational and RD investment costs. - Trader Community Insights - Cổng thông tin điện tử tỉnh Lào Cai

Thu, 16 Apr 2026
Apimeds Pharmaceuticals Warns of Delayed 2025 Annual Report - TipRanks

Thu, 16 Apr 2026
Apimeds Pharmaceuticals US notifies late 10-K filing, expects NYSE American noncompliance notice - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.